Allovir, Inc.

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR) today announced that Augustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year. Although officially leaving the company, Dr. Melian has agreed to work with AlloVir in an advisory capacity to ensure a smooth transition. Dr. Melian joined AlloVir in March 2019 and under his leadership, the company has advanced its lead product posoleucel into Phase 3 clinical development and shaped the clinical deve

AlloVir Announces Departure of Chief Medical Officer Augustin Melian

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary data from the ongoing open-label portion of a Phase 2 study assessing the safety and efficacy of posoleucel (Viralym-M, ALVR105) for the prevention of clinically significant infections and end-organ diseases from six potentially life-threatening viruses in high-risk patients following allogeneic hematopoietic cell transplantation (allo-HCT). Out of

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced it will host a virtual investor event on Monday, December 13, 2021, at 8:00 a.m. EST. The event will feature an AlloVir corporate update and a review of initial data from a Phase 2 study of posoleucel for multi-virus prevention that will be presented at the American Society of Hematology (ASH) Annual Meeting on Saturday, December 11, 2021. Posoleucel is an investigational virus-s

AlloVir to Host Virtual Investor Event

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that the company will participate in the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded fireside chat will be available from Monday, November 22 to Thursday, December 2, 2021, on the conference website and on the Investors & Press section of the AlloVir website at https://ir.allovir.com. About AlloVir AlloVir is a leading late clinical-

AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the third quarter ended September 30, 2021. The company also shared progress on the advancement of its prioritized virus-specific T cell (VST) programs to prevent or treat life-threatening viral diseases. “AlloVir's allogeneic, off-the-shelf, virus-specific T cell platform has the potential to transform the care of and outcomes for patients – from stem cell

AlloVir Reports Third Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to posoleucel (Viralym-M, ALVR105) for the treatment of virus-associated hemorrhagic cystitis (HC). Posoleucel is an investigational, allogeneic, off-the-shelf, multi-virus specific T cell therapy under development for the treatment and prevention of serious diseases caused by six d

FDA Grants Orphan Drug Designation (ODD) to AlloVir's Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis

My readers will get the background on the stem cell transplant issues. I will offer a discussion on the uniqueness that AlloVir offers patients. The outstanding caliber and experience the management team brings to the creation of the company will be shared.

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced preclinical and early clinical data demonstrating that ALVR109, an investigational, allogeneic, off-the-shelf, virus-specific T cell (VST) therapy targeting SARS-CoV-2, provides antiviral activity and coverage against multiple variant strains, including Delta. The data were featured today in an oral presentation at IDWeek™ 2021. Preclinical research from Baylor College of

Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir's Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate update at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14th at 4:15 p.m. ET. The presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay of the presentation will be available for approximately 30 days following the presentation. About AlloVir AlloVir is a

AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

New York, New York--(Newsfile Corp. - August 26, 2021) - Levi & Korsinsky announces it has commenced an investigation of Avalara, Inc. (NASDAQ: ALVR) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/avalara-inc-information-request-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Avalara, Inc. - ALVR

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2021. “We believe virus-specific T-cell therapies can have a meaningful impact in treating as well as preventing multiple devastating viral infections. This approach is groundbreaking in the field of stem cell transplantation – and has the potential to transform care for patients and health care providers,” said Dr. Diana B

AlloVir Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the first quarter ended March 31, 2021. “The first quarter of 2021 was one of significant progress for AlloVir and moved us closer towards our ambition to transform the lives of patients suffering from devastating and life-threatening viral diseases,” said David Hallal, Chief Executive Officer and Chairman of the Board, AlloVir. “The appointment of Dr. Dian

AlloVir Reports First Quarter 2021 Financial Results

Uses same technology as MRKR, which I covered earlier. Has a later stage and much more successful program in infectious diseases in HSCT patients.

AlloVir: Targeting Infectious Diseases In Stem Cell Transplant Patients

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that its Board of Directors has appointed Diana M. Brainard, M.D., as the company's Chief Executive Officer (CEO), effective May 17, 2021. Dr. Brainard has served on AlloVir's Board of Directors since April 2019, initially as a Board Observer, and as an Independent Director since July 2020. Dr. Brainard currently serves as Senior Vice President and Head of the Virology Therapeu

AlloVir Appoints Diana M. Brainard, M.D.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021 at 4:20 p.m. ET. The presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay of the presentation will be available for approximately 30 days following the presentation. About AlloVir AlloVir is

AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced results of a subgroup analysis from a Phase 2, proof-of-concept study (CHARMS) evaluating the company's lead product candidate, Viralym-M (ALVR105), an allogeneic, off-the-shelf, multi-virus specific investigational T-cell therapy (VST), in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients with virus-associated hemorrhagic cystitis (V-HC). These data are bein

AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today provided a corporate update and reported full-year 2020 financial results for the period ended December 31, 2020. “Since completing our initial public offering in 2020, our team achieved our ambitious milestones, as planned. These milestones included obtaining clearance from the U.S. Food and Drug Administration (FDA) for two Investigational New Drug (IND) applications, initiating three

AlloVir Reports Full Year 2020 Financial Results

Absolute Software

Agrify

Fathom Holdings

1847 GOEDEKER INC.

Li Auto Inc.

MEDIROM Healthcare Technologies

SAP SE

Vertex, Inc.

Vital Farms, Inc.

Vasta Platform Limited

Qualtrics International

The US IPO market is expected to remain active in the week ahead with eight IPOs slated to raise $4.6 billion. Street research is expected for Medirom Healthcare Technologies on Monday, 1/25.

U.S. IPO Week Ahead: Diverse 8 IPO Week Features 3 Billion-Dollar Deals

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster presentation during the Transplantation & Cellular Therapy Meeting of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) taking place virtually February 8 – 12, 2021. Details of the oral presentations are as follows: Pres

AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021 at 9:10 a.m. ET. An audio-only webcast of the presentation will be available on January 11th on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay of the presentation will be available for approximately 30 days following the presen

AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ALVR106, an allogeneic, off-the-shelf virus-specific T cell therapy (VST) designed to target infections and diseases caused by respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). The IND enables AlloVir to initiate a Ph

AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses

--(BUSINESS WIRE)--AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company's innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's techn

Company Profile for AlloVir

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that results from the Phase 2, proof-of-concept CHARMS study demonstrated that an allogeneic, off-the-shelf, multi-virus specific T cell therapy, Viralym-M (ALVR105), achieved a 93% clinical response and was generally well-tolerated in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients with at least one drug refractory infection. The findings were highlight

Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at the 62nd American Society of Hematology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that preclinical data presented in an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting, demonstrates selective antiviral activity of ALVR109 –the company's virus-specific T cell therapy designed to combat SARS-CoV-2, the virus responsible for COVID-19. The data presented found that the SARS-CoV-2 virus-specific T cell therapy, ALVR109, was able

Preclinical Data Demonstrate Anti-Viral Activity of AlloVir's ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020. The presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3 and will also be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay of the pr

News for Allovir, Inc. Stock (ALVR)